Rep. Emily Randall Sells Off Shares of Amgen Inc. (NASDAQ:AMGN)

Representative Emily Randall (D-Washington) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Amgen Trading Up 0.6 %

Shares of NASDAQ:AMGN opened at $296.97 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The business’s fifty day simple moving average is $273.29 and its 200-day simple moving average is $302.18. The company has a market capitalization of $159.63 billion, a PE ratio of 39.33, a P/E/G ratio of 3.01 and a beta of 0.56. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts predict that Amgen Inc. will post 20.59 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.21%. Amgen’s dividend payout ratio (DPR) is currently 119.21%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AMGN. UBS Group dropped their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Wolfe Research began coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Redburn Partners dropped their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft dropped their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Piper Sandler boosted their price target on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $314.09.

Insider Activity at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the sale, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,405 shares of company stock valued at $10,410,596. 0.69% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in Amgen in the 3rd quarter worth $25,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter worth about $29,000. Ritter Daniher Financial Advisory LLC DE raised its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Finally, Synergy Investment Management LLC acquired a new position in shares of Amgen during the 4th quarter worth about $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.